Comparing clinicians’ use of an anticoagulation management service and usual care in ambulatory oncology

Abstract

Purpose:

There is no consensus in the oncology community about the optimal model for anticoagulation management of ambulatory cancer patients. To understand oncologists’ preferences regarding anticoagulation management, we compared the characteristics of patients referred to an oncology-oriented anticoagulation management service with “usual care” patients managed by the patient’s primary oncologist.

Methods:

We performed a retrospective medical record review of ambulatory oncology patients’ anticoagulation care at a comprehensive cancer center. We examined the characteristics of 33 patients anticoagulated before implementation of a dedicated oncology anticoagulation management service. We compared this group with 33 patients managed by the anticoagulation management service and with 39 usual care patients managed by the primary oncologist after the anticoagulation management service was created. We also examined differences in laboratory test utilization, time in the therapeutic range (for patients anticoagulated with warfarin), and anticoagulation-related adverse events during a 3-month assessment period.

Results:

Anticoagulation management service patients were more likely to be treated for hematologic malignancies, use erythropoietin stimulating agents, and require warfarin management for previous venous thromboembolic disease compared to usual care patients. In contrast, oncologists were more likely to manage anticoagulation care of patients with advanced solid tumors undergoing active chemotherapy. Anticoagulation management service and usual care patients on warfarin therapy had comparable time in the therapeutic range and complication rates.

Conclusion:

Oncologists selectively referred patients to the anticoagulation management service. Anticoagulation management service patients’ warfarin control and complication rates were comparable to care provided by the primary oncologist, suggesting that an oncology-specific anticoagulation management service may be a feasible and effective option for anticoagulation management of ambulatory oncology patients.

Keywords

Anticoagulant medication safety adverse drug event health care management

Get full access to this article

View all access options for this article.

References

Streiff

. Anticoagulation in the management of venous thromboembolism in the cancer patient. J Thromb Thrombolysis 2011; 31: 282–294.

Kuderer

Ortel

Francis

. Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J Clin Oncol 2009; 27: 4902–4911.

Prandoni

Lensing

AWA

Piccioli

. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3484–3488.

Zhou

Teegala

Huen

. Incidence and risk factors of venous thromboembolic events in lymphoma. Am J Med 2010; 123: 935–941.

Deitcher

. Cancer and thrombosis: mechanisms and treatment. J Thromb Thrombolysis 2003; 16: 21–31.

Nalluri

Chu

Keresztes

. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008; 300: 2277–2285.

Streiff

. Anticoagulation in the management of venous thromboembolism in the cancer patient. J Thromb Thrombolysis 2011; 31: 282–294.

Hurwitz

Saltz

Van Cutsem

. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol 2011; 29: 1757–1764.

Coleman

MacCallum

. Treatment and secondary prevention of venous thromboembolism in cancer. Br J Cancer 2010; 102 Suppl. 1 S17–S23.

10.

Khorana

. Cancer and thrombosis: implications of published guidelines for clinical practice. Ann Oncol 2009; 20: 1619–1630.

11.

Lyman

Khorana

Falanga

. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25: 5490–5505.

12.

Bergqvist

Agnelli

Cohen

. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002; 346: 975–980.

13.

Akl

Rohilla

Maddalena

. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer: a systematic review. Cancer 2008; 113: 1685–1694.

14.

Lee

Levine

Baker

. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146–153.

15.

Hutten

Prins

Gent

. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000; 18: 3078–3083.

16.

Connolly

Ezekowitz

Yusuf

. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139–1151.

17.

Schulman

Kearon

Kakkar

. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342–2352.

18.

The RE-MOBILIZE Writing Committee. Oral thrombin inhibitor debigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009; 24: 1–9.

19.

Granger

Alexander

McMurray

. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981–992.

20.

Patel

Mahaffey

Garg

. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883–891.

21.

Noble

Shelley

Coles

. Management of venous thromboembolism in patients with advanced cancer: a systematic review and meta-analysis. Lancet Oncol 2008; 9: 577–584.

22.

Jones

Barnett

Gauthier

. Clinical outcomes of a pharmacist-managed anticoagulation service for breast cancer patients. J Oncol Pharm Pract 2012; 18: 122–127.

23.

Rosendaal

Cannegieter

Van Der Meer

. A method to determine the optimal density of oral anticoagulant therapy. Thromb Haemostas 1993; 69: 236–239.

24.

Meyer

Marianovic

Vlacke

. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Int Med 2002; 162: 1729–1735.

25.

Rose

Sharman

Ozonoff

. Effectiveness of warfarin among patients with cancer. J Gen Intern Med 2007; 22: 997–1002.

26.

Chiquette

Amato

Bussey

. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med 1998; 158: 1641–1647.

27.

Menzin

Boulanger

Hauch

. Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: a multi-site managed-care study. Ann Pharmacother 2005; 39: 446–451.

28.

Ansell

Hughes

. Evolving models of warfarin management: anticoagulation clinics, patient self-monitoring, and patient self-management. Am Heart J 1996; 132: 1095–1100.

29.

Lafata

Martin

Kaatz

. The cost-effectiveness of different management strategies for patients on chronic warfarin therapy. J Gen Intern Med 2000; 15: 31–37.